首页> 美国卫生研究院文献>Theranostics >Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis
【2h】

Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis

机译:Caspase反应智能分子探针在药物诱导的正电子发射断层显像中的合理设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: Positron emission tomography (PET) imaging of apoptosis is very important for early evaluation of tumor therapeutic efficacy. A stimuli-responsive probe based on the peptide sequence Asp-Glu-Val-Asp (DEVD), [18F]DEVD-Cys(StBu)-PPG(CBT)-AmBF3 ([18F]>1), for PET imaging of tumor apoptosis was designed and prepared. This study aimed to develop a novel smart probe using a convenient radiosynthesis method and to fully examine the sensitivity and specificity of the probe response to the tumor treatment.>Methods: The radiolabelling precursor DEVD-Cys(StBu)-PPG(CBT)-AmBF3 (>1) was synthesized through multistep reactions. The reduction together with caspase-controlled macrocyclization and self-assembly of >1 was characterized and validated in vitro. After [18F]fluorination in the buffer (pH= 2.5), the radiolabelling yield (RLY), radiochemical purity (RCP) and stability of the probe [18F]>1 in PBS and mouse serum were investigated by radio-HPLC. The sensitivity and specificity of [18F]>1 for detecting the drug-induced apoptosis was fully evaluated in vitro and in vivo. The effect of cold precursor >1 on the cell uptake and tumor imaging of [18F]>1 was also assessed. The level of activated caspase-3 in Hela cells and tumors with or without apoptosis induction was analyzed and compared by western blotting and histological staining.>Results: The whole radiosynthesis process of [18F]>1 was around 25 min with RLY of 50%, RCP of over 99% and specific activity of 1.45 ± 0.4 Ci/µmol. The probe was very stable in both PBS and mouse serum within 4 h. It can be activated by caspase-3 and then undergo an intermolecular cyclization to form nanosized particles. The retained [18F]>1 in DOX-treated HeLa cells was 2.2 folds of that in untreated cells. Within 1 h microPET imaging of the untreated Hela-bearing mice, the injection of [18F]>1 resulted in the increase of the uptake ratio of tumor to muscle (T/M) only from 1.74 to 2.18, while in the DOX-treated Hela-bearing mice T/M increased from 1.88 to 10.52 and the co-injection of [18F]>1 and >1 even led to the increase of T/M from 3.08 to 14.81.>Conclusions: A caspase-responsive smart PET probe [18F]>1 was designed and prepared in a kit-like manner. Co-injection of [18F]>1 and 1 generated remarkably enhanced tumor uptake and signal-to-noise ratio in the tumor-bearing mice with drug-induced apoptosis, which correlated well with the expression level of activated caspase-3. This early readout of treatment response ensured that the probe [18F]>1 could serve as a promising PET imaging probe for timely and noninvasive evaluation of tumor therapy.
机译:>目的:凋亡的正电子发射断层扫描(PET)成像对于早期评估肿瘤治疗效果非常重要。基于肽序列Asp-Glu-Val-Asp(DEVD),[ 18 F] DEVD-Cys(StBu)-PPG(CBT)-AmBF3([ 18 F] > 1 ),设计并制备了用于肿瘤细胞凋亡的PET成像。这项研究旨在开发一种使用方便的放射合成方法的新型智能探针,并全面检查该探针对肿瘤治疗的敏感性和特异性。>方法::放射性标记前体DEVD-Cys(StBu)-通过多步反应合成了PPG(CBT)-AmBF3(> 1 )。还原并结合胱天蛋白酶控制的大环化和> 1 的自组装在体外进行了表征和验证。在缓冲液中[ 18 F]氟化后(pH = 2.5),探针[ 18 F]的放射性标记产率(RLY),放射化学纯度(RCP)和稳定性。用放射-HPLC法检测PBS和小鼠血清中的> 1 。在体内和体外充分评估了[ 18 F] > 1 对检测药物诱导的细胞凋亡的敏感性和特异性。还评估了冷前体> 1 对[ 18 F] > 1 的细胞摄取和肿瘤显像的影响。通过免疫印迹和组织学染色分析并比较了有无凋亡诱导作用的Hela细胞和肿瘤中活化的caspase-3的水平。>结果:[ 18 F] > 1 大约25分钟,RLY为50%,RCP超过99%,比活为1.45±0.4 Ci / µmol。该探针在PBS和小鼠血清中均在4小时内非常稳定。它可以被caspase-3激活,然后进行分子间环化以形成纳米尺寸的颗粒。 DOX处理的HeLa细胞中保留的[ 18 F] > 1 是未处理细胞的2.2倍。未经治疗的Hela荷瘤小鼠在1 h microPET成像中,注射[ 18 F] > 1 导致肿瘤对肌肉的摄取率增加(T / M)仅从1.74增至2.18,而在接受DOX处理的带有Hela的小鼠中,T / M从1.88增至10.52,并且同时注射[ 18 F] > 1 和> 1 甚至导致T / M从3.08增加到14.81。>结论:胱天蛋白酶敏感的智能PET探针[ 18 F ] > 1 的设计和制作方法类似于套件。 [ 18 F] > 1 和1的共同注射在荷瘤小鼠中诱导了药物诱导的凋亡,从而显着增强了肿瘤的摄取和信噪比,从而与活化的caspase-3的表达水平密切相关。这种对治疗反应的早期读数确保了探针[ 18 F] > 1 可以作为有前途的PET成像探针,用于及时,无创地评估肿瘤治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号